CN112575576A - 一种具有光热/铜协同抗菌功能的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法 - Google Patents
一种具有光热/铜协同抗菌功能的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法 Download PDFInfo
- Publication number
- CN112575576A CN112575576A CN202110057734.3A CN202110057734A CN112575576A CN 112575576 A CN112575576 A CN 112575576A CN 202110057734 A CN202110057734 A CN 202110057734A CN 112575576 A CN112575576 A CN 112575576A
- Authority
- CN
- China
- Prior art keywords
- polylactic acid
- fiber membrane
- nano
- copper
- composite fiber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000835 fiber Substances 0.000 title claims abstract description 76
- 229920000747 poly(lactic acid) Polymers 0.000 title claims abstract description 75
- 239000004626 polylactic acid Substances 0.000 title claims abstract description 75
- 239000012528 membrane Substances 0.000 title claims abstract description 63
- 239000010949 copper Substances 0.000 title claims abstract description 60
- 229910052802 copper Inorganic materials 0.000 title claims abstract description 58
- 239000002131 composite material Substances 0.000 title claims abstract description 53
- 229920001690 polydopamine Polymers 0.000 title claims abstract description 40
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 title claims abstract description 29
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 230000002195 synergetic effect Effects 0.000 title claims abstract description 13
- 238000010041 electrostatic spinning Methods 0.000 claims abstract description 22
- 239000002105 nanoparticle Substances 0.000 claims abstract description 9
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 36
- 239000000243 solution Substances 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 21
- 229960003638 dopamine Drugs 0.000 claims description 18
- 239000011259 mixed solution Substances 0.000 claims description 17
- 238000001035 drying Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- FYFFGSSZFBZTAH-UHFFFAOYSA-N methylaminomethanetriol Chemical compound CNC(O)(O)O FYFFGSSZFBZTAH-UHFFFAOYSA-N 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 7
- 238000010907 mechanical stirring Methods 0.000 claims description 7
- 239000012691 Cu precursor Substances 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical group [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 5
- 238000005520 cutting process Methods 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 230000005686 electrostatic field Effects 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 238000009987 spinning Methods 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 4
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 claims description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 3
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 claims description 3
- 229960001701 chloroform Drugs 0.000 claims description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 2
- 229910001069 Ti alloy Inorganic materials 0.000 claims description 2
- 229910000883 Ti6Al4V Inorganic materials 0.000 claims description 2
- 239000007983 Tris buffer Substances 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 150000001879 copper Chemical class 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 239000010935 stainless steel Substances 0.000 claims description 2
- 229910001220 stainless steel Inorganic materials 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000010936 titanium Substances 0.000 claims description 2
- 229910052719 titanium Inorganic materials 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 230000008901 benefit Effects 0.000 abstract description 5
- 229910021645 metal ion Inorganic materials 0.000 abstract description 5
- 230000004043 responsiveness Effects 0.000 abstract description 4
- 206010059866 Drug resistance Diseases 0.000 abstract description 3
- 230000009920 chelation Effects 0.000 abstract description 3
- 239000011664 nicotinic acid Substances 0.000 abstract description 3
- 229940124350 antibacterial drug Drugs 0.000 abstract description 2
- 210000000988 bone and bone Anatomy 0.000 description 18
- 238000005457 optimization Methods 0.000 description 8
- 230000008439 repair process Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 6
- 239000013557 residual solvent Substances 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 206010031252 Osteomyelitis Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 239000012620 biological material Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- XTVVROIMIGLXTD-UHFFFAOYSA-N copper(II) nitrate Chemical compound [Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XTVVROIMIGLXTD-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920002961 polybutylene succinate Polymers 0.000 description 2
- 239000004631 polybutylene succinate Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000037408 Device failure Diseases 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000002121 nanofiber Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- -1 polybutylene succinate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
Images
Classifications
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M11/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising
- D06M11/83—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising with metals; with metal-generating compounds, e.g. metal carbonyls; Reduction of metal compounds on textiles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/047—Other specific metals or alloys not covered by A61L27/042 - A61L27/045 or A61L27/06
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/0007—Electro-spinning
- D01D5/0015—Electro-spinning characterised by the initial state of the material
- D01D5/003—Electro-spinning characterised by the initial state of the material the material being a polymer solution or dispersion
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/0007—Electro-spinning
- D01D5/0061—Electro-spinning characterised by the electro-spinning apparatus
- D01D5/0076—Electro-spinning characterised by the electro-spinning apparatus characterised by the collecting device, e.g. drum, wheel, endless belt, plate or grid
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/0007—Electro-spinning
- D01D5/0061—Electro-spinning characterised by the electro-spinning apparatus
- D01D5/0092—Electro-spinning characterised by the electro-spinning apparatus characterised by the electrical field, e.g. combined with a magnetic fields, using biased or alternating fields
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/42—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
- D04H1/4326—Condensation or reaction polymers
- D04H1/435—Polyesters
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/70—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres
- D04H1/72—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged
- D04H1/728—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged by electro-spinning
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M15/00—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment
- D06M15/19—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment with synthetic macromolecular compounds
- D06M15/37—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M16/00—Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M2101/00—Chemical constitution of the fibres, threads, yarns, fabrics or fibrous goods made from such materials, to be treated
- D06M2101/16—Synthetic fibres, other than mineral fibres
- D06M2101/30—Synthetic polymers consisting of macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- D06M2101/32—Polyesters
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Textile Engineering (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Mechanical Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Artificial Filaments (AREA)
Abstract
本发明公开了一种具有光热/铜协同抗菌功能的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法，该方法综合了聚乳酸良好的生物相容性和可降解性，聚多巴胺对金属离子的螯合作用和还原性，铜纳米粒子的广谱抗菌性、抗细菌耐药性和对近红外光的响应性等各自特点，以及静电纺丝技术在构建形貌可控的仿生纤维结构方面的独特优势，制备的复合纤维膜能模拟体内的天然细胞外基质，加速血管生成和刺激骨形成，且通过光热/纳米铜协同抗细菌感染，从而促进骨组织修复，作为骨修复材料能广泛应用于骨损伤修复和骨缺损治疗领域。
Description
技术领域
本发明涉及一种医用高分子复合材料的制备方法，特别是涉及一种具有光热/铜协同抗菌功能的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法。
背景技术
全世界数百万患者患有骨疾病或骨缺损，骨修复材料的研发是亟需解决的难题，理想的人工骨合成生物材料应该具有良好的生物相容性、生物活性、骨诱导性和抗菌性。
聚乳酸（Polylactic acid，PLLA）由于其良好的生物相容性、可生物降解、无毒等优点，已经被美国食品药品监督管理局（FDA）批准用于临床应用，在临床上主要应用于引导骨组织再生、药物输送、软组织修复等，是目前人工骨生物医用材料的研究热点之一，但缺乏骨诱导和抗菌性能，这限制了它在骨组织工程中的应用。
聚多巴胺(Polydopamine, PDA)通过多巴胺自聚合得到，具有一定的还原能力和抗菌性，而且能够响应近红外光。由于具有邻苯二酚的结构特点，聚多巴胺被广泛用于基底表面修饰，用以改善材料与基底间的粘附性；此外邻苯二酚的结构对金属离子具有螯合作用，可以原位还原和稳定金属离子，同时由于聚多巴胺具有亲水性基团-NH2和-OH，还可用于改善材料的亲水性能。
骨感染是临床骨修复过程中急需攻克的难题，由于细菌所引起的骨感染会损害骨组织的愈合修复能力，导致植入物植入失败，因此研发具有抗菌性能的植入材料成为目前研究热点之一。骨感染主要由细菌感染引起，及时有效的杀死组织表面的细菌并抑制细菌生物膜的形成是抑制感染、促进骨组织愈合的关键所在。目前常见的治疗骨感染的方法是清创术和全身抗生素治疗，但在长期或过度使用抗生素会增加手术风险和产生耐药。因此，提高生物材料的细菌耐药性、抗骨感染能力成为亟待解决的难题。铜是人体必需的微量元素，铜纳米粒子(Copper nanoparticles, Cu-NPs)具有广泛的抗菌性和抗细菌耐药性能，且对近红外光具有响应性，在临床上被应用于杀灭生物材料上的细菌，其杀菌机制首先是铜Cu-NPs在细菌的细胞膜中积累和溶解，改变了细菌膜的通透性杀死细菌，其次水在Cu-NPs的近红外光的催化作用下产生了活性氧导致蛋白质功能障碍，从而杀死细菌，Cu-NPs对近红外光有响应，使得近红外光被吸收转化为热，进一步加强杀菌效果。值得注意的是，铜可以从死细菌中游离出来并重复上述循环，能够实现持久抗菌；此外铜纳米粒子还可以刺激骨的形成，促进血管生成，从而进一步促进骨组织修复。因此将铜纳米粒子引入骨修复复合材料能赋予后者快速、持久抗菌性能和成骨性能。
静电纺丝技术可构建形貌可控、有类似于天然细胞外基质(Extracellularmatrix, ECM)的纤维结构，设计理想的仿生环境用于细胞粘附和增殖，促进新组织生长。温和的工艺条件使静电纺丝技术在包封药物时保持分子结构完整性方面具有明显的优势，且纳米纤维在一定程度上可以减缓药物的释放，在骨组织工程中具有重要的应用价值。
基于此，综合聚乳酸良好的生物相容性和可降解性，聚多巴胺对金属离子的高亲和力、还原能力和近红外光响应性，铜纳米粒子的广谱抗菌性、抗细菌耐药性和光热效应等各自特点，以及静电纺丝技术在构建形貌可控的仿生纤维结构方面的独特优势，本发明提供一种具有光热/铜协同抗菌功能的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法。
发明内容
本发明的目的在于提供一种具有光热/铜协同抗菌功能的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法，基于静电纺丝技术将具有还原、螯合能力的聚多巴胺和光热协同抗菌剂铜纳米粒子负载到生物相容性和可降解性优越的聚乳酸基纤维膜上，该骨修复材料能广泛应用于骨损伤修复和骨缺损治疗领域。
本发明通过下述的技术方案来实现：
一种具有光热/铜协同抗菌功能的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法，包括如下步骤：
（1）将聚乳酸溶于有机溶剂中，机械搅拌使其完全溶解，得到均匀的聚乳酸静电纺丝溶液；
（2）以步骤（1）所得聚乳酸静电纺丝溶液为原料进行静电纺丝，得到聚乳酸纤维膜；
（3）将步骤（2）所得的聚乳酸纤维膜在真空条件下干燥完全后，将所得的纤维膜剪成一定尺寸的块状，保存在37℃的恒温箱中备用；
（4）将三羟甲基氨基甲烷溶于去离子水中，机械搅拌使其完全溶解，用盐酸调节溶液pH至8-9之间；
（5）将多巴胺加入步骤（4）所得的三羟甲基氨基甲烷溶液中，机械搅拌使其完全溶解，然后加入纳米铜前驱体，继续搅拌使溶解，并形成均一稳定的混合溶液；
（6）将步骤（3）所得的块状聚乳酸纤维膜浸泡于步骤（5）所得的混合溶液中，在恒温水浴下加热至反应完全，得到聚乳酸/聚多巴胺/纳米铜复合纤维膜；
（7）将步骤（6）所得的复合纤维膜在真空条件下干燥完全后，保存在37℃的恒温箱中备用。
作为本发明技术方案的进一步优化，步骤（1）中所述聚乳酸的加入浓度范围为100-220 g/L，步骤（4）中所述三羟甲基氨基甲烷的加入浓度范围为1.0-1.5 g/L，步骤（5）中所述多巴胺的加入浓度范围为0.8-1.2 g/L，纳米铜前驱体的加入浓度范围为0.6-1.0g/L。
作为本发明技术方案的进一步优化，步骤（1）中所述的有机溶剂为三氟乙醇、六氟异丙醇、二氯甲烷、三氯甲烷、N, N-二甲基甲酰胺或二甲基亚砜中的至少一种。
作为本发明技术方案的进一步优化，步骤（1）、步骤（4）和步骤（5）中所述的机械搅拌转速范围为600-1600 r/min，其中步骤（1）的搅拌时间为10-24 h，步骤（4）的搅拌时间为2-4 h，步骤（5）的搅拌时间为6-8min。
作为本发明技术方案的进一步优化，步骤（2）中所述的静电纺丝参数包括，高压静电场电压范围12-20 kv，纺丝接收间距10-20 cm，注射器推进速度2-4 mL/h，收集器的材质为钛、钛合金Ti6Al4V、铝或不锈钢。
作为本发明技术方案的进一步优化，步骤（5）中所述的纳米铜前驱体为可溶于水铜盐的至少一种。
作为本发明技术方案的进一步优化，步骤（6）中所述的恒温水浴的温度范围为80-100℃，加热时间为1-3 h。
作为本发明技术方案的进一步优化，步骤（3）和步骤（7）中所述的真空干燥温度为60-80℃，干燥时间为48-96 h。
作为本发明技术方案的进一步优化，所述纳米铜为铜单质纳米粒子。
综上所述，本发明复合纤维膜的制备方法的优点在于：基于静电纺丝技术制备了一种具有光热/铜协同抗菌功能的聚多巴胺/聚乳酸/纳米铜复合纤维膜，该复合纤维膜能模拟体内的天然细胞外基质，促进成骨和血管生成，达到快速并持久抗细菌感染的效果，从而促进骨组织修复。该制备方法操作简便，成本低廉，制得的复合纤维作为骨修复材料具有良好的应用前景。
附图说明
图1为本发明的实施例一制得的复合纤维膜的扫描电镜（SEM）图片；
图2为本发明的实施例一制得的复合纤维膜的能谱（EDS）图；
图3为本发明的实施例一制得的复合纤维膜矿化5天之后形貌的扫描电镜（SEM）图片；
图4为本发明的实施例一制得的复合纤维膜接收近红外光照射以后温度随时间变化曲线图。
具体实施方式
下面将结合本发明实施例，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
实施例一
本发明提供一种具有光热/铜协同抗菌功能的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法，包括如下步骤：
（1）将1.44 g聚乳酸溶于于9 mL三氟乙醇中，使用转速1300r/min的机械搅拌16 h使其完全溶解，得到均匀的聚乳酸静电纺丝溶液；
（2）以步骤（1）所得聚乳酸静电纺丝溶液为原料进行静电纺丝，其参数为高压静电场电压15kv，纺丝接收间距13 cm，注射器推进速度3 mL/h，得到附着于钛箔收集器表面的聚乳酸纤维膜；
（3）将步骤（2）所得的聚乳酸纤维膜在70℃下真空干燥72 h以完全除去残余溶剂，然后将所得的纤维膜剪成2 cm×2 cm的块状，保存在37℃的恒温箱中备用；
（4）将1.21 g三羟甲基氨基甲烷溶于1000 mL去离子水中，使用转速1000r/min的机械搅拌2 h使其完全溶解，然后用1 mol/L的盐酸调节溶液pH至8.5；
（5）将1.00 g多巴胺加入步骤（4）所得的三羟甲基氨基甲烷溶液中，使用转速1000r/min的机械搅拌3 h使其完全溶解，然后加入0.79 g的硝酸铜，继续搅拌6min使溶解，并形成均一稳定的混合溶液；
（6）取步骤（5）所得的混合溶液50 mL，将步骤（3）所得的2 cm×2 cm聚乳酸纤维膜完全浸入其中，在90℃的恒温水浴下加热1 h，得到聚乳酸/聚多巴胺/纳米铜复合纤维膜；
（7）将步骤（6）所得的复合纤维膜70℃下真空干燥72 h以完全除去残余溶剂，然后保存在37℃的恒温箱中备用。
如图1-4所示，图1为聚乳酸/聚多巴胺/纳米铜复合纤维的SEM图，从图中可以看出，复合纤维上的铜纳米颗粒分布较为均匀，尺寸较小，其抗菌性会越好；图2为聚乳酸/聚多巴胺/纳米铜复合纤维的EDS图，从图中可以看出，复合纤维上的铜元素分布较为均匀；图3为聚乳酸/聚多巴胺/纳米铜复合纤维矿化5天之后的形貌图，从图中可以看出，复合纤维表面几乎被钙磷酸盐覆盖，这是由于聚多巴胺对金属离子有很高的亲和力，吸引了钙磷酸盐的沉积，且聚多巴胺对钙离子有界面浓缩的作用，吸引了更多的钙磷盐沉积，说明聚乳酸/聚多巴胺/纳米铜具有良好的生物活性；图4为接收近红外光照射以后温度随时间变化曲线图，从图中可以看出，当复合纤维接受功率为1W、频率为808 nm的近红外光照射10min时，PLLA/PDA/Cu复合纤维比聚丁二酸丁二醇酯（PBS）和PLLA纤维在相同时间时具有较高的温度，说明PDA对近红外光具有一定的响应性，但光产生热的效果不佳，而PLLA/PDA/Cu复合纤维的温度达到了48.2℃，接近杀死细菌的温度且在人体组织可承受的温度范围内，说明铜吸收了近红外光后将光转化为了热，结合铜的物理杀菌作用，会使得铜在更短的时间内快速杀死细菌。
实施例二
本发明提供一种具有光热/铜协同抗菌功能的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法，包括如下步骤：
（1）将1.81 g聚乳酸溶于于15 mL二甲基亚砜中，使用转速1000r/min的机械搅拌20 h使其完全溶解，得到均匀的聚乳酸静电纺丝溶液；
（2）以步骤（1）所得聚乳酸静电纺丝溶液为原料进行静电纺丝，其参数为高压静电场电压12kv，纺丝接收间距15 cm，注射器推进速度2 mL/h，得到附着于钛箔收集器表面的聚乳酸纤维膜；
（3）将步骤（2）所得的聚乳酸纤维膜在80℃下真空干燥96 h以完全除去残余溶剂，然后将所得的纤维膜剪成4 cm×4 cm的块状，保存在37℃的恒温箱中备用；
（4）将1.38 g三羟甲基氨基甲烷溶于1000 mL去离子水中，使用转速1200r/min的机械搅拌3 h使其完全溶解，然后用1 mol/L的盐酸调节溶液pH至8.0；
（5）将0.92 g多巴胺加入步骤（4）所得的三羟甲基氨基甲烷溶液中，使用转速1200r/min的机械搅拌2 h使其完全溶解，然后加入0.85 g的硝酸铜，继续搅拌7min使溶解，并形成均一稳定的混合溶液；
（6）取步骤（5）所得的混合溶液100 mL，将步骤（3）所得的4 cm×4 cm聚乳酸纤维膜完全浸入其中，在80℃的恒温水浴下加热2 h，得到聚乳酸/聚多巴胺/纳米铜复合纤维膜；
（7）将步骤（6）所得的复合纤维膜60℃下真空干燥72 h以完全除去残余溶剂，然后保存在37℃的恒温箱中备用。
实施例三
本发明提供一种具有光热/铜协同抗菌功能的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法，包括如下步骤：
（1）将6.56 g聚乳酸溶于36 mL六氟异丙醇和三氯甲烷的等比例混溶液中中，使用转速1500r/min的机械搅拌12 h使其完全溶解，得到均匀的聚乳酸静电纺丝溶液；
（2）以步骤（1）所得聚乳酸静电纺丝溶液为原料进行静电纺丝，其参数为高压静电场电压18kv，纺丝接收间距14 cm，注射器推进速度4 mL/h，得到附着于钛箔收集器表面的聚乳酸纤维膜；
（3）将步骤（2）所得的聚乳酸纤维膜在80℃下真空干燥96 h以完全除去残余溶剂，然后将所得的纤维膜剪成3 cm×3 cm的块状，保存在37℃的恒温箱中备用；
（4）将1.47 g三羟甲基氨基甲烷溶于1000 mL去离子水中，使用转速800r/min的机械搅拌4 h使其完全溶解，然后用1 mol/L的盐酸调节溶液pH至9.0；
（5）将0.81 g多巴胺加入步骤（4）所得的三羟甲基氨基甲烷溶液中，使用转速800r/min的机械搅拌3 h使其完全溶解，然后加入0.98 g的硝酸铜，继续搅拌8min使溶解，并形成均一稳定的混合溶液；
（6）取步骤（5）所得的混合溶液50 mL，将步骤（3）所得的3 cm×3 cm聚乳酸纤维膜完全浸入其中，在85℃的恒温水浴下加热3 h，得到聚乳酸/聚多巴胺/纳米铜复合纤维膜；
（7）将步骤（6）所得的复合纤维膜60℃下真空干燥72 h以完全除去残余溶剂，然后保存在37℃的恒温箱中备用。
以上所述仅为本发明的较佳实施例而已，并不用以限制本发明的范围，任何本领域的技术人员，凡在不脱离本发明的精神和原则之前提下，所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
Claims (9)
1.一种具有光热/铜协同抗菌功能的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法，其特征在于，包括如下步骤：
（1）将聚乳酸溶于有机溶剂中，机械搅拌使其完全溶解，得到均匀的聚乳酸静电纺丝溶液；
（2）以步骤（1）所得聚乳酸静电纺丝溶液为原料进行静电纺丝，得到聚乳酸纤维膜；
（3）将步骤（2）所得的聚乳酸纤维膜在真空条件下干燥完全后，将所得的纤维膜剪成一定尺寸的块状，保存在37℃的恒温箱中备用；
（4）将三羟甲基氨基甲烷溶于去离子水中，机械搅拌使其完全溶解，用盐酸调节溶液pH至8-9之间；
（5）将多巴胺加入步骤（4）所得的三羟甲基氨基甲烷溶液中，机械搅拌使其完全溶解，然后加入纳米铜前驱体，继续搅拌使溶解，并形成均一稳定的混合溶液；
（6）将步骤（3）所得的块状聚乳酸纤维膜浸泡于步骤（5）所得的混合溶液中，在恒温水浴下加热至反应完全，得到聚乳酸/聚多巴胺/纳米铜复合纤维膜；
（7）将步骤（6）所得的复合纤维膜在真空条件下干燥完全后，保存在37℃的恒温箱中备用。
2.根据权利要求1所述的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法，其特征在于：步骤（1）中所述聚乳酸的加入浓度范围为100-220 g/L，步骤（4）中所述三羟甲基氨基甲烷的加入浓度范围为1.0-1.5 g/L，步骤（5）中所述多巴胺的加入浓度范围为0.8-1.2 g/L，纳米铜前驱体的加入浓度范围为0.6-1.0 g/L。
3.根据权利要求1所述的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法，其特征在于：步骤（1）中所述的有机溶剂为三氟乙醇、六氟异丙醇、二氯甲烷、三氯甲烷、N, N-二甲基甲酰胺或二甲基亚砜中的至少一种。
4.根据权利要求1所述的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法，其特征在于：步骤（1）、步骤（4）和步骤（5）中所述的机械搅拌转速范围为600-1600 r/min，其中步骤（1）的搅拌时间为10-24 h，步骤（4）的搅拌时间为2-4 h，步骤（5）的搅拌时间为6-8min。
5.根据权利要求1所述的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法，其特征在于：步骤（2）中所述的静电纺丝参数包括，高压静电场电压范围12-20 kv，纺丝接收间距10-20 cm，注射器推进速度2-4 mL/h，收集器的材质为钛、钛合金Ti6Al4V、铝或不锈钢。
6.根据权利要求1或2所述的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法，其特征在于：步骤（5）中所述的纳米铜前驱体为可溶于水铜盐的至少一种。
7.根据权利要求1所述的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法，其特征在于：步骤（6）中所述的恒温水浴的温度范围为80-100℃，加热时间为1-3 h。
8.根据权利要求1所述的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法，其特征在于：步骤（3）和步骤（7）中所述的真空干燥温度为60-80℃，干燥时间为48-96 h。
9.根据权利要求1-8任一项所述的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法，其特征在于：所述纳米铜为铜单质纳米粒子。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110057734.3A CN112575576B (zh) | 2021-01-15 | 2021-01-15 | 一种具有光热/铜协同抗菌功能的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110057734.3A CN112575576B (zh) | 2021-01-15 | 2021-01-15 | 一种具有光热/铜协同抗菌功能的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112575576A true CN112575576A (zh) | 2021-03-30 |
| CN112575576B CN112575576B (zh) | 2023-11-24 |
Family
ID=75145136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110057734.3A Active CN112575576B (zh) | 2021-01-15 | 2021-01-15 | 一种具有光热/铜协同抗菌功能的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112575576B (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114344544A (zh) * | 2022-01-05 | 2022-04-15 | 四川大学 | 光激活抗菌敷料及其制备方法 |
| CN114438782A (zh) * | 2022-03-24 | 2022-05-06 | 新疆师范大学 | 一种快速抗菌/抗氧化活性的聚乳酸/单宁酸/铁/半胱氨酸骨诱导复合纤维膜的制备方法 |
| CN115029930A (zh) * | 2022-07-06 | 2022-09-09 | 广东药科大学 | 生物可降解的PLLA/Ag/Cu2+复合膜及其制备方法和应用 |
| CN116695445A (zh) * | 2023-06-16 | 2023-09-05 | 南通宗杰纺织科技有限公司 | 二氧化硫气体协同光热抗菌织物的制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105200663A (zh) * | 2015-11-04 | 2015-12-30 | 上海洁晟环保科技有限公司 | 抗菌纳米纤维膜的制备方法 |
| CN107137764A (zh) * | 2017-05-11 | 2017-09-08 | 芜湖扬展新材料科技服务有限公司 | 一种多巴结构修饰聚乳酸组织修复材料的制备方法 |
| US20180344632A1 (en) * | 2015-11-27 | 2018-12-06 | Medprin Regenerative Medical Technologies Co., Ltd. | Tissue repair fiber membrane, preparation method and application thereof, and tissue repair product |
| CN110644239A (zh) * | 2019-10-31 | 2020-01-03 | 南昌大学附属口腔医院(江西省口腔医院) | 一种抗菌聚乳酸纳米纤维及其制备方法和应用 |
-
2021
- 2021-01-15 CN CN202110057734.3A patent/CN112575576B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105200663A (zh) * | 2015-11-04 | 2015-12-30 | 上海洁晟环保科技有限公司 | 抗菌纳米纤维膜的制备方法 |
| US20180344632A1 (en) * | 2015-11-27 | 2018-12-06 | Medprin Regenerative Medical Technologies Co., Ltd. | Tissue repair fiber membrane, preparation method and application thereof, and tissue repair product |
| CN107137764A (zh) * | 2017-05-11 | 2017-09-08 | 芜湖扬展新材料科技服务有限公司 | 一种多巴结构修饰聚乳酸组织修复材料的制备方法 |
| CN110644239A (zh) * | 2019-10-31 | 2020-01-03 | 南昌大学附属口腔医院(江西省口腔医院) | 一种抗菌聚乳酸纳米纤维及其制备方法和应用 |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114344544A (zh) * | 2022-01-05 | 2022-04-15 | 四川大学 | 光激活抗菌敷料及其制备方法 |
| CN114344544B (zh) * | 2022-01-05 | 2022-12-02 | 四川大学 | 光激活抗菌敷料及其制备方法 |
| CN114438782A (zh) * | 2022-03-24 | 2022-05-06 | 新疆师范大学 | 一种快速抗菌/抗氧化活性的聚乳酸/单宁酸/铁/半胱氨酸骨诱导复合纤维膜的制备方法 |
| CN114438782B (zh) * | 2022-03-24 | 2023-05-02 | 新疆师范大学 | 一种快速抗菌/抗氧化活性的聚乳酸/单宁酸/铁/半胱氨酸骨诱导复合纤维膜的制备方法 |
| CN115029930A (zh) * | 2022-07-06 | 2022-09-09 | 广东药科大学 | 生物可降解的PLLA/Ag/Cu2+复合膜及其制备方法和应用 |
| CN115029930B (zh) * | 2022-07-06 | 2024-04-16 | 广东药科大学 | 生物可降解的PLLA/Ag/Cu2+复合膜及其制备方法和应用 |
| CN116695445A (zh) * | 2023-06-16 | 2023-09-05 | 南通宗杰纺织科技有限公司 | 二氧化硫气体协同光热抗菌织物的制备方法 |
| CN116695445B (zh) * | 2023-06-16 | 2023-10-31 | 南通宗杰纺织科技有限公司 | 二氧化硫气体协同光热抗菌织物的制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112575576B (zh) | 2023-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112575576A (zh) | 一种具有光热/铜协同抗菌功能的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法 | |
| Shuai et al. | Accelerated degradation of HAP/PLLA bone scaffold by PGA blending facilitates bioactivity and osteoconductivity | |
| EP1799277B1 (en) | Porous biomaterial-filler composite and a method for making the same | |
| Chesnutt et al. | Composite chitosan/nano-hydroxyapatite scaffolds induce osteocalcin production by osteoblasts in vitro and support bone formation in vivo | |
| Venugopal et al. | Biomimetic hydroxyapatite-containing composite nanofibrous substrates for bone tissue engineering | |
| KR100762928B1 (ko) | 견 피브로인 나노섬유로 이루어진 부직포 형태의 골조직유도 재생용 차폐막 및 그 제조방법 | |
| KR101053118B1 (ko) | 골 재생용 실크/하이드록시아파타이트 복합 나노섬유 지지체의 제조방법 | |
| Xin et al. | Novel layer-by-layer structured nanofibrous mats coated by protein films for dermal regeneration | |
| CN104631118B (zh) | 一种可吸收的抗菌海藻纤维 | |
| CN114438782B (zh) | 一种快速抗菌/抗氧化活性的聚乳酸/单宁酸/铁/半胱氨酸骨诱导复合纤维膜的制备方法 | |
| CN112402699A (zh) | 一种具有骨诱导和抗菌功能的聚乳酸/地塞米松/纳米金属复合纤维膜的制备方法 | |
| Hoang Phuc et al. | Fabrication of hyaluronan-poly (vinylphosphonic acid)-chitosan hydrogel for wound healing application | |
| CN111386133B (zh) | 制备骨传导性纤维制品的方法和包含此类骨传导性纤维制品的医用植入物 | |
| Fan et al. | Biomaterial-based scaffolds as antibacterial suture materials | |
| Aghajanian et al. | A 3D macroporous and magnetic Mg2SiO4-CuFe2O4 scaffold for bone tissue regeneration: Surface modification, in vitro and in vivo studies | |
| CN112898619A (zh) | 具有抗菌及成骨整合性能的生物材料及其制备方法和应用 | |
| CN114288481B (zh) | 一种多层复合载药引导骨再生膜及其制备方法 | |
| CN112190762B (zh) | 一种注射型镁基复合纤维强化磷酸钙生物骨粘合剂及其制备方法和应用 | |
| Lian et al. | In vivo osteogenesis of vancomycin loaded nanohydroxyapatite/collagen/calcium sulfate composite for treating infectious bone defect induced by chronic osteomyelitis | |
| CN113301928B (zh) | 生物支架和用于制备其的方法 | |
| Zhang et al. | Bioinspired fabrication of EDC-crosslinked gelatin/nanohydroxyapatite injectable microspheres for bone repair | |
| Naghibzadeh | Nanofibers for Skin Regeneration. | |
| Johnson et al. | Surface modification and coatings for controlling the degradation and bioactivity of magnesium alloys for medical applications | |
| CN111118649A (zh) | 一种复合纳米纤维骨支架及其制备方法 | |
| CN113425894A (zh) | 一种具有逐步抗菌和促进骨再生功能的骨组织工程支架及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |